Lisa Cavacini to HIV Infections
This is a "connection" page, showing publications Lisa Cavacini has written about HIV Infections.
Connection Strength
1.956
-
Yu X, Duval M, Gawron M, Posner MR, Cavacini LA. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition. J Immunol Res. 2016; 2016:9425172.
Score: 0.324
-
Duval M, Lewis CJ, Nomellini JF, Horwitz MS, Smit J, Cavacini LA. Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus. Antimicrob Agents Chemother. 2011 Dec; 55(12):5547-52.
Score: 0.233
-
Cavacini LA, Duval M, Patil A, Wood C, Mayer KH, Ruprecht RM, Posner MR. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy. J Med Virol. 2005 Jun; 76(2):146-52.
Score: 0.151
-
Cavacini L, Posner M. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. AIDS Res Hum Retroviruses. 2004 Apr; 20(4):435-41.
Score: 0.139
-
Cavacini LA, Kuhrt D, Duval M, Mayer K, Posner MR. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res Hum Retroviruses. 2003 Sep; 19(9):785-92.
Score: 0.134
-
Cavacini L, Duval M, Song L, Sangster R, Xiang SH, Sodroski J, Posner M. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS. 2003 Mar 28; 17(5):685-9.
Score: 0.130
-
Cavacini LA, Wisnewski A, Peterson JE, Montefiori D, Emes C, Duval M, Kingsbury G, Wang A, Scadden D, Posner MR. A human anti-HIV autoantibody enhances EBV transformation and HIV infection. Clin Immunol. 1999 Dec; 93(3):263-73.
Score: 0.103
-
Cavacini LA, Peterson JE, Nappi E, Duval M, Goldstein R, Mayer K, Posner MR. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals. J Virol. 1999 Nov; 73(11):9638-41.
Score: 0.102
-
Gawron MA, Duval M, Carbone C, Jaiswal S, Wallace A, Martin JC, Dauphin A, Brehm MA, Greiner DL, Shultz LD, Luban J, Cavacini LA. Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1. J Immunol. 2019 02 01; 202(3):799-804.
Score: 0.097
-
Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, Posner MR. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses. 1998 Sep 20; 14(14):1271-80.
Score: 0.095
-
Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, Hammer S, Koziel C, Trapnell C, Posner MR. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses. 1998 May 01; 14(7):545-50.
Score: 0.092
-
Cavacini LA, Emes CL, Power J, Underdahl J, Goldstein R, Mayer K, Posner MR. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr (1988). 1993 Oct; 6(10):1093-102.
Score: 0.067
-
Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li PL, Williams AL, Hofmann-Lehmann R, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology. 2007 Feb 05; 358(1):69-78.
Score: 0.041
-
Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS. 2003 Feb 14; 17(3):301-9.
Score: 0.032
-
Kitabwalla M, Ferrantelli F, Wang T, Chalmers A, Katinger H, Stiegler G, Cavacini LA, Chou TC, Ruprecht RM. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):125-31.
Score: 0.032
-
Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, Ruprecht RM. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol. 2001 Aug; 30(4):190-6.
Score: 0.029
-
Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol. 2001 Aug; 8(4):350-8.
Score: 0.029
-
Xu W, Smith-Franklin BA, Li PL, Wood C, He J, Du Q, Bhat GJ, Kankasa C, Katinger H, Cavacini LA, Posner MR, Burton DR, Chou TC, Ruprecht RM. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol. 2001 Mar-Apr; 4(2):55-61.
Score: 0.028
-
Wisnewski A, Cavacini L, Posner M. Human antibody variable region gene usage in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 01; 11(1):31-8.
Score: 0.020
-
Cavacini LA, Power J, Emes CL, Mace K, Treacy G, Posner MR. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J Immunother Emphasis Tumor Immunol. 1994 May; 15(4):251-6.
Score: 0.017
-
Cavacini LA, Emes CL, Power J, Duval M, Posner MR. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J Immunol. 1994 Mar 01; 152(5):2538-45.
Score: 0.017
-
Farr C, Nomellini JF, Ailon E, Shanina I, Sangsari S, Cavacini LA, Smit J, Horwitz MS. Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors. PLoS One. 2013; 8(6):e65965.
Score: 0.016
-
Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A. 2011 Jul 05; 108(27):11181-6.
Score: 0.014
-
Nomellini JF, Li C, Lavallee D, Shanina I, Cavacini LA, Horwitz MS, Smit J. Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alpha. PLoS One. 2010 Apr 28; 5(4):e10366.
Score: 0.013